FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 濱海投資有限公司 (於百慕達註冊成立之有限公司) FF305 確認 不適用 第一章節註釋： 若股份曾以超過一個每股價格發行/出售/購回/贖回，則須提供每股成交量加權平均價格。 若購回/贖回股份將於期終結存日期之後購回/贖回結算完成之時予以註銷，則該等購回/贖回股份仍屬A部所述期終結存當日的已發行股份的一部分。該等購回/贖回股份的詳情應在B部作 出披露。 呈交日期： 2026年1月14日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 不適用 | | 於香港聯交所上市 ...

Group 1 - The article discusses the share buybacks conducted by various companies on January 13, 2026, with Tencent Holdings (00700) having the largest buyback amount of 636 million yuan for 1.012 million shares [1][2] - Other notable companies involved in the buyback include Xiaomi Group (01810) with 4 million shares repurchased for 152 million yuan, and Sunny Optical Technology (02382) with 640,000 shares for approximately 41.79 million yuan [1][2] - The total number of shares repurchased by Tencent Holdings in the year reached 11 million, representing 1.199% of its total share capital [2] Group 2 - The buyback activities reflect a strategic move by companies to enhance shareholder value and signal confidence in their financial health [1][2] - Companies like Weigao Group (01066) and Xinli International (00732) also showed significant buyback activity, with Weigao repurchasing 27,440 shares for 1.4962 million yuan, representing 6.519% of its total share capital [2] - The data indicates a trend among companies to engage in share buybacks as a method to return capital to shareholders and potentially boost stock prices [1][2][3]

Core Viewpoint - Binhai Investment (02886) announced the acquisition of Hegia, a pioneer in siRNA drug development, for a maximum base price of RMB 12 million, which will enhance the company's innovation in chronic disease management and clinical advancement [1][2]. Group 1: Acquisition Details - The acquisition involves Binhai Investment's wholly-owned subsidiary, Chengda Pharmaceutical Investment (Beijing) Co., Ltd., purchasing 100% of Hegia's shares, with part of the payment in cash and part in shares [1]. - Hegia will become an indirect wholly-owned subsidiary of Binhai Investment upon completion of the acquisition [1]. Group 2: Hegia's Technology and Market Potential - Hegia specializes in siRNA technology, which addresses limitations in existing chronic disease therapies, with a projected global transaction volume in the siRNA field exceeding USD 35 billion by 2025, reflecting a growth rate of over 40% [2]. - Hegia has developed a differentiated delivery platform with proprietary technology, including the MVIP platform for long-acting liver-targeted delivery, which addresses patient compliance issues in chronic disease treatment [3]. Group 3: Clinical Assets and Pipeline - Hegia possesses four clinical-stage assets and over ten preclinical assets, all with first-in-class and best-in-class potential [4]. - Key clinical assets include Kylo-11, a long-acting siRNA for treating elevated lipoprotein(a) levels, currently in Phase II trials, and Kylo-12, targeting high triglycerides, expected to start Phase II trials in mid-2026 [5][6].

Core Viewpoint - Binhai Investment (02886) announced a share buyback plan, indicating confidence in its stock value and potential for future growth [1] Group 1: Share Buyback Details - The company will repurchase 66,000 shares at a total cost of HKD 75.3 million [1] - The buyback price per share ranges from HKD 1.14 to HKD 1.15 [1]

Group 1 - The company Binhai Investment (02886.HK) announced a share buyback on January 13, 2026, spending HKD 75,300 to repurchase 66,000 shares [1] - The buyback price ranged from HKD 1.14 to HKD 1.15 per share [1]

Group 1 - The company Binhai Investment (02886) announced a share buyback plan, committing to repurchase 66,000 shares at a total cost of HKD 75.3 million [1] - The buyback price per share is set between HKD 1.14 and HKD 1.15 [1]

FF305 確認 不適用 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 濱海投資有限公司 (於百慕達註冊成立之有限公司) 呈交日期： 2026年1月13日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02886 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份） ...

滨海投资(02886)发布公告，于2026年1月12日，该公司斥资2.51万港元回购2.2万股。 ...

智通财经APP讯，滨海投资(02886)发布公告，于2026年1月12日，该公司斥资2.51万港元回购2.2万股。 ...

格隆汇1月12日丨滨海投资(02886.HK)发布公告，2026年1月12日以2.51万港元回购2.2万股，回购价格每 股1.14港元。 ...